AdamsonJones, the growing East-Midlands based firm of intellectual property (IP) specialists has recently welcomed two new recruits to its Leicester and Nottingham teams. Peter Banks joins the firm’s Leicester office to train as a patent attorney, working mainly with mechanical, materials and electrical technologies. Peter already has several years’ experience...
Nottingham drug discovery and chemistry firm has sights set on continued expansion
Founded two decades ago by an academic duo, Charnwood Molecular is today a rapidly growing synthetic chemistry firm. It started out, as many business ventures, from humble beginnings. But today, bioscience firm Charnwood Molecular is providing cutting edge medicinal chemistry services for clients across the globe, with drug discovery just...
MHRA Inspection success for Nottingham’s Upperton Pharma Solutions
Upperton Pharma Solutions’ new pharmaceutical spray drying manufacturing facilities at Nottingham Science and Technology Park have successfully passed inspection by the UK Medicines and Healthcare products Regulatory Agency (MHRA). A pharmaceutical spray drying contract development and manufacturing organisation (CDMO), Upperton Pharma Solutions moved to its new facilities on Nottingham Science...
Further Funding for Medical Technology Trials in Nottinghamshire and Derbyshire
Medical technology companies in Nottinghamshire and Derbyshire can apply to cover 50% of their clinical evaluation costs, thanks to a project delivered by Medilink East Midlands and part-funded by the European Regional Development Fund (ERDF) and the East Midlands Academic Health Science Network (EMAHSN). Medical Technology Trial (MTT) grants are...
Medilink East Midlands will continue to inspire life science companies in Derbyshire and Nottinghamshire
Life science companies in Derbyshire and Nottinghamshire can become ‘inspired’ with their business operations, thanks to a project delivered by Medilink East Midlands and part-funded by the European Regional Development Fund (ERDF). Inspiring Networking to Stimulate Technology Innovation in Life Sciences (INSTILS) is a £7.39million scheme, part-funded by ERDF, to...
ABHI’s US Accelerator set to target Tennessee
Following the success of ABHI’s work in Texas, which has seen a host of companies forge new business relationships and research partnerships, the US Accelerator programme will now target the State of Tennessee. Taking place from 24th – 29th March 2019, the mission is part of the ABHI’s broader engagement...
Texas proves the gateway to stateside success for UK HealthTech
Clinical trials, research collaborations, new partnerships and sales are all outcomes from the Association of British HealthTech Industries (ABHI) work in Texas. Last week, a cohort of British HealthTech companies and medical institutions took part in the tenth mission to the State to showcase medical devices, diagnostic software and digitally-enabled...
New Chief Executive Officer appointed by D2N2 Local Enterprise Partnership
A new Chief Executive Officer has been appointed by the D2N2 Local Enterprise Partnership. Sajeeda Rose, who has been Interim CEO at the D2N2 LEP since September (2018), becomes CEO with immediate effect, following a robust recruitment process. As the LEP’s CEO Sajeeda leads a small team supporting the D2N2...
No Deal Update from the Office of Life Sciences
The Secretary of State for Health and Social Care, Matt Hancock, has this week written to suppliers of medicines, medical devices and clinical consumables with a progress update on the Government’s contingency planning approach. This includes an update on changes to cross-Government planning assumptions about potential border delays, should the...
Quotient Sciences Constructs State-of-the-Art Early-Phase Formulation and Manufacturing Facility in U.S.
Quotient Sciences, a leading drug development services organisation, announces a significant expansion to its operations in the U.S. with the opening of a state-of-the-art, 45,000-square-foot facility located near Philadelphia, in Garnet Valley, Pa. The $15 million investment will create a center of excellence for early-phase formulation development and clinical trial...
